Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 38

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Asthma+1

Recruiting

Study on Azithromycin for Treating Hospitalized Children Aged 1-5 with Asthma Symptoms

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Azithromycin
  • Sponsor:Rigshospitalet

Conjunctivitis allergic+3

Not yet recruiting

Efficacy and safety of 6‑grass pollen polymerized extracts 30,000 TU/mL and 10,000 TU/mL in adults with grass pollen‑induced allergic rhinitis/rhinoconjunctivitis, with or without mild‑to‑moderate asthma

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Bilastine
  • Sponsor:Inmunotek S.L.

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years

Cough

Not yet recruiting

A Randomized Dose‑Ranging Study of Nalbuphine Hydrochloride Extended‑Release Tablets in Adults with Refractory Chronic Cough

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Nalbuphine Hydrochloride
  • Sponsor:Trevi Therapeutics Inc.

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Asthma

Not yet recruiting

Study comparing fluticasone furoate and vilanterol inhalation powder with BREO ELLIPTA in adults with asthma to evaluate their therapeutic equivalence and safety

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Fluticasone Furoate
  • Sponsor:Sandoz Private Limited

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Human metapneumovirus, virus-like protein
  • Sponsor:AstraZeneca AB

Systemic scleroderma+1

Not yet recruiting

Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Scleroderma Research Foundation

Seasonal allergy

Not yet recruiting

Study on the Effectiveness of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis and Possible Asthma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Non-small cell lung cancer

Not yet recruiting

Study on the Effects and Safety of Cemiplimab and BNT116 in Adults with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Small cell lung cancer

Not yet recruiting

A Phase 3 Trial of BL-M14D1 and Atezolizumab vs Standard Therapy in First‑Line Extensive‑Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Systimmune Inc.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.